Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman talks to Proactive about how the clinical-stage biopharmaceutical company plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome, known officially as Post-Acute Sequelae of COVID-19.
Dr Lederman says Tonix plans to meet with the FDA in the third quarter of 2021 fo the design of a potential Phase 2 pivotal study for Long COVID.